Why Do We Need Another PD-1/PD-L1 Inhibitor?

 Back  View
Why Do We Need Another PD-1/PD-L1 Inhibitor?
 VIDEO   00:12:56   10/2021
 View

BeiGene - Why Do We Need Another PD-1/PD-L1 Inhibitor?

Sunday, September 19, 2021 | 10:30–12:00 (CEST)

 

Ross Soo
Senior Consultant, Department of Haematology-Oncology, NCIS
Principal Investigator, Cancer Science Institute of Singapore, NUS

Rating

Rate this resource

Related resources

How will the new wave of PD-1 inhibitors change the treatment landscape in NSCLC?
How will the new wave of PD-1 inhibitors change the treatment landscape in NSCLC?
One molecule, many mechanisms of action: Why all PD-1 inhibitors are not the same
One molecule, many mechanisms of action: Why all PD-1 inhibitors are not the same
Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
 Back